Noncoding RNA Regulation of Ferroptotic Vulnerability in Oxaliplatin-Resistant Colorectal Cancer: A Critical Narrative Review Beyond the Canonical ceRNA Model
Litsenziya: cc-by-nc-nd
Annotatsiya
Oxaliplatin (OXA) resistance remains a major limitation in colorectal cancer (CRC), and ferroptosis is being investigated as a potential therapeutic vulnerability. Non-coding RNAs (ncRNAs) may influence ferroptotic sensitivity through redox metabolism, iron homeostasis, lipid remodeling, and tumor–microenvironment interactions. However, many proposed ncRNA-mediated mechanisms, particularly competing endogenous RNA (ceRNA) models, remain insufficiently validated. This critical narrative review synthesizes selected experimental reports and is not a systematic or exhaustive review. The reports discussed were organized into four evidence categories: direct ncRNA–OXA–ferroptosis investigations; OXA–ferroptosis studies without ncRNA perturbation; ncRNA–ferroptosis studies without OXA testing; and ncRNA–OXA studies lacking ferroptosis-specific validation. These categories describe the directness of evidence, not formal study-quality scores. Among the selected reports, only two linked ncRNA regulation with both OXA response and ferroptosis: SNHG4 via PTEN RNA stability and lncRNA-HMG via p53–MDM2 and SLC7A11/VKORC1L1 regulation. Neither demonstrated a complete PI3K/AKT–NRF2–SLC7A11/GPX4 pathway or endogenous ceRNA competition. Other studies implicated NRF2/GPX4, SLC7A11, ACSL4-dependent lipid remodeling, iron regulation, FSP1, DHODH, mitochondrial metabolism, microbiota, and extracellular vesicles. Given heterogeneity in models, treatments, endpoints, and validation, links across studies remain hypothesis-generating. Overall, the evidence supports a context-dependent ferroptotic-threshold framework rather than a universal ncRNA-driven pathway. Future work should use endogenous ncRNA perturbation, quantitative ceRNA validation, ferroptosis-specific rescue, and patient-derived models.
Hali tarjima qilinmagan